Amarin Corporation PLC is a pharmaceutical company that focuses on developing and commercializing therapeutics for cardiovascular health. The company's core values revolve around innovation, ethical practices, and patient-centric approaches. Amarin aims to improve the lives of patients suffering from cardiovascular diseases by providing effective and safe treatment options. With its dedication to scientific research and development, Amarin strives to deliver high-quality pharmaceutical solutions that meet global healthcare needs. By prioritizing patient well-being and upholding strong values of integrity, Amarin Corporation PLC aims to make a positive impact in the pharmaceutical industry.

Amarin Corporation PLC is primarily present in multiple countries and regions globally. The company has a significant presence and operates in the United States, Europe, and certain Asian markets. With its headquarters in Dublin, Ireland, Amarin Corporation PLC has expanded its operations and established a strong market presence in the United States, particularly focusing on the development and commercialization of pharmaceutical products. Moreover, the company has steadily grown its footprint in various European countries, including the United Kingdom, Germany, France, and Spain, among others. Overall, Amarin Corporation PLC's global presence underscores its commitment to delivering innovative healthcare solutions to a diverse range of markets.

Amarin Corporation PLC, a leading pharmaceutical company, has achieved several significant milestones. The company successfully developed and gained approval for Vascepa, a prescription medicine used for various cardiovascular conditions. Amarin has also conducted extensive clinical trials, showcasing Vascepa's effectiveness in reducing the risk of cardiovascular events. Furthermore, the company secured a favorable patent litigation outcome, strengthening its market exclusivity for Vascepa. Amarin's strong market presence and continuous research and development efforts position it as a key player in the cardiovascular pharmaceutical industry.

Amarin Corporation PLC is a pharmaceutical company focused on developing innovative treatments for cardiovascular diseases. Established in 1989, Amarin has made significant advancements in the field of lipid science, particularly in relation to high triglyceride levels. The company's flagship product, Vascepa, is an FDA-approved prescription medication used to reduce triglyceride levels in adults with severe hypertriglyceridemia. Amarin Corporation PLC utilizes its expertise in lipid science to enhance patient care and improve cardiovascular health worldwide. With a strong commitment to research and development, Amarin continues to progress in the pharmaceutical industry, aiming to provide effective solutions for cardiovascular diseases.

The main competitors of Amarin Corporation PLC in the market include companies like AstraZeneca, Novartis, and Pfizer. These pharmaceutical giants are also active in the cardiovascular and metabolic diseases sector, where Amarin operates. AstraZeneca offers drugs like Crestor and Farxiga, while Novartis has drugs like Entresto and Exforge in a similar therapeutic class. Pfizer's Lipitor and Norvasc are also prominent competitors in the market. Amarin Corporation PLC faces stiff competition from these industry leaders as it strives to maintain its market share and drive growth in the cardiovascular pharmaceutical space.

Amarin Corporation PLC is primarily active in the pharmaceutical industry.

Amarin Corporation PLC operates as a biopharmaceutical company specializing in the development and commercialization of therapeutics for improving cardiovascular health. The company's business model focuses on the research, development, and marketing of prescription drugs derived from its proprietary technology and expertise in lipid science and omega-3 fatty acids. Amarin Corporation PLC aims to address unmet medical needs in treating hypertriglyceridemia and reducing cardiovascular risk. By leveraging its strong scientific foundation, Amarin strives to bring innovative, clinically proven therapies to market, ultimately benefiting patients and healthcare providers worldwide.

Amarin Corporation의 P/E 비율은 -5.2입니다.

Amarin Corporation의 P/S 비율은 1.55입니다.

Amarin Corporation에 대한 AlleAktien 품질 점수는 1/10입니다.

예상되는 Amarin Corporation 매출은 206.16 백만 USD입니다.

예상되는 Amarin Corporation 이익은 -61.47 백만 USD입니다.

Amarin Corporation PLC is a global biopharmaceutical company specializing in the development of therapeutic treatments for cardiovascular diseases. The company is headquartered in Dublin, Ireland and has branches in the USA and other countries worldwide. The business model of Amarin focuses on marketing Vascepa, a unique patented drug consisting of pure ethyl-EPA. Vascepa is used to treat high triglycerides (a type of fat in the blood) in patients with a specific type of heart disease. It is the only FDA-approved prescription medication that contains pure ethyl-EPA as the active ingredient. The company has a three-part business strategy. Firstly, the company focuses on maximizing the sales of Vascepa by increasing sales in the USA and expanding into other countries. This is done through intensive marketing campaigns targeting specific doctors and through a strategic partnership with clinicians. Secondly, the company plans to expand the product development pipeline by researching and developing new applications and formulations of Vascepa. The company also aims to develop methods to investigate and test the effectiveness of the medication. These investments will also improve the results of clinical trials to promote the approval of Vascepa for additional indications. Thirdly, the company is working to protect its intellectual property rights. The company currently holds several patents in the USA and other countries worldwide, which protect Vascepa and provide an additional source of income. The company is willing to go to court to defend its patents and obtain compensation from competitors who infringe on its patents. Overall, Amarin is a company specialized in the development, manufacturing, and marketing of medications with the goal of improving quality of life and reducing the risk of heart diseases. The company relies on comprehensive research and development to offer its customers a better product overall. The company is an international player with a wide range of products. The various divisions of Amarin are closely aligned to meet the needs of customers and to drive the company forward. The US Food and Drug Administration (FDA) has granted approval since 2012. Since 2020, Vascepa has also been approved in Europe. The company plans for stronger growth through an ambitious market presence and investments in research and development. With this strategy, Amarin promises a higher growth rate and an optimized gross profit in the future.

Amarin Corporation은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Amarin Corporation의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Amarin Corporation의 ISIN은 US0231112063입니다.

Amarin Corporation의 WKN은 A0NBNG입니다.

Amarin Corporation의 티커는 AMRN입니다.

지난 12개월 동안 Amarin Corporation은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Amarin Corporation은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Amarin Corporation의 현재 배당 수익률은 입니다.

Amarin Corporation은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Amarin Corporation은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Amarin Corporation은 '건강' 섹터에 속합니다.

Amarin Corporation의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Amarin Corporation는 0 USD를 배당금으로 지급했습니다.

Amarin Corporation의 배당금은 USD에 지급됩니다.